JP2003529602A - ガランタミンの新規誘導体および類似体 - Google Patents

ガランタミンの新規誘導体および類似体

Info

Publication number
JP2003529602A
JP2003529602A JP2001572510A JP2001572510A JP2003529602A JP 2003529602 A JP2003529602 A JP 2003529602A JP 2001572510 A JP2001572510 A JP 2001572510A JP 2001572510 A JP2001572510 A JP 2001572510A JP 2003529602 A JP2003529602 A JP 2003529602A
Authority
JP
Japan
Prior art keywords
nmr
mmol
alkyl
cdcl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001572510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529602A5 (enExample
Inventor
ヨルディス、ウルリヒ
フレーリヒ、ヨハネス
トロイ、マティアス
ヒルンシャル、マンフレッド
クツォルナー、ラズロ
ケルツ、ベアーテ
ベルツィヒ、シュテファン
Original Assignee
ザノヒェミア・ファルマツォイティカ・アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザノヒェミア・ファルマツォイティカ・アーゲー filed Critical ザノヒェミア・ファルマツォイティカ・アーゲー
Publication of JP2003529602A publication Critical patent/JP2003529602A/ja
Publication of JP2003529602A5 publication Critical patent/JP2003529602A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2001572510A 2000-03-31 2001-03-22 ガランタミンの新規誘導体および類似体 Pending JP2003529602A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AT546/2000 2000-03-31
AT5462000 2000-03-31
AT2382001 2001-02-15
AT238/2001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (de) 2000-03-31 2001-03-22 Neue derivate und analoga von galanthamin

Publications (2)

Publication Number Publication Date
JP2003529602A true JP2003529602A (ja) 2003-10-07
JP2003529602A5 JP2003529602A5 (enExample) 2006-10-05

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001572510A Pending JP2003529602A (ja) 2000-03-31 2001-03-22 ガランタミンの新規誘導体および類似体

Country Status (26)

Country Link
US (2) US7166588B2 (enExample)
EP (1) EP1181294B1 (enExample)
JP (1) JP2003529602A (enExample)
CN (1) CN1380883A (enExample)
AT (1) ATE263171T1 (enExample)
AU (1) AU785385B2 (enExample)
BG (1) BG65134B1 (enExample)
BR (1) BR0105563A (enExample)
CA (1) CA2368966A1 (enExample)
CZ (1) CZ300160B6 (enExample)
DE (1) DE50101827D1 (enExample)
DK (1) DK1181294T3 (enExample)
ES (1) ES2215885T3 (enExample)
HK (1) HK1049832A1 (enExample)
HU (1) HUP0202233A3 (enExample)
IS (1) IS2287B (enExample)
MX (1) MXPA01012275A (enExample)
NO (1) NO326458B1 (enExample)
NZ (1) NZ516302A (enExample)
PL (1) PL202463B1 (enExample)
PT (1) PT1181294E (enExample)
RU (1) RU2241001C2 (enExample)
SI (1) SI1181294T1 (enExample)
SK (1) SK285909B6 (enExample)
TR (1) TR200400857T4 (enExample)
WO (1) WO2001074820A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
MXPA04009254A (es) * 2002-03-25 2005-06-08 Sanochemia Pharmazeutika Ag Procedimiento para la obtencion de norgalantamina, derivados de norgalantamina asi como sus isomeros.
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel
CA2721007C (en) 2008-04-14 2014-04-29 Galantos Pharma Gmbh Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
CN107066241B (zh) 2010-06-15 2021-03-09 起元技术有限责任公司 用于动态加载基于图的计算的系统和方法
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
CN106170762B (zh) 2013-12-05 2020-01-14 起元技术有限责任公司 管理包括子图的数据流图所用的接口
SG11201701662XA (en) 2014-09-02 2017-04-27 Ab Initio Technology Llc Visually specifying subsets of components in graph-based programs through user interactions
WO2016036826A1 (en) 2014-09-02 2016-03-10 Ab Initio Technology Llc Compiling graph-based program specifications
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands
CN116082352A (zh) * 2023-02-16 2023-05-09 西南交通大学 一种加兰他敏衍生物及其制备方法和用途
CN118908968B (zh) * 2024-10-09 2025-03-04 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法
CN119528922B (zh) * 2024-11-22 2025-12-09 泰安汉威集团有限公司 一种氢溴酸加兰他敏关键杂质-氢溴酸表加兰他敏的手性合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02503794A (ja) * 1987-05-04 1990-11-08 デイービス、ボニー アルツハイマー病の治療のための化合物
JPH06507621A (ja) * 1991-05-14 1994-09-01 スノラソン　エルニア ベンゾジアゼピンによる治療における改善
WO1999007359A1 (en) * 1997-08-08 1999-02-18 Shire International Licensing B.V. Use of cholinesterase inhibitors for treating attention deficit disorders
JPH11509541A (ja) * 1995-07-19 1999-08-24 ソシエテ ド コンセイユ ド ルシエルシエ エ ダアツプリカーシヨン シヤンテイフイツク（エス．セー．エール．アー．エス．） 新規なガランタミン誘導体、その製造方法、その医薬としての用途及びそれを含有する医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) * 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
SK283877B6 (sk) * 1994-10-21 2004-04-06 Sanochemia Pharmazeutika Ag Spôsob výroby derivátov 4a,5,9,10,11,12,-hexahydro-6H- benzofuro[3a,3,2-ef][2]benzazepínu
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02503794A (ja) * 1987-05-04 1990-11-08 デイービス、ボニー アルツハイマー病の治療のための化合物
JPH06507621A (ja) * 1991-05-14 1994-09-01 スノラソン　エルニア ベンゾジアゼピンによる治療における改善
JPH11509541A (ja) * 1995-07-19 1999-08-24 ソシエテ ド コンセイユ ド ルシエルシエ エ ダアツプリカーシヨン シヤンテイフイツク（エス．セー．エール．アー．エス．） 新規なガランタミン誘導体、その製造方法、その医薬としての用途及びそれを含有する医薬組成物
WO1999007359A1 (en) * 1997-08-08 1999-02-18 Shire International Licensing B.V. Use of cholinesterase inhibitors for treating attention deficit disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009066981, Ｊｏｕｒｎａｌ ｏｆ Ｈｅｔｅｒｏｃｙｃｌｉｃ Ｃｈｅｍｉｓｔｒｙ, 1973, Ｖｏｌ．１０， Ｎｏ．１, ｐ．３５−３７ *
JPN6009066984, Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ， Ｓｅｃｔｉｏｎ Ｃ： Ｏｒｇａｎｉｃ Ｃｈｅｍｉｓｔｒｙ, 1971, Ｎｏ．６, ｐ．１０４３−１０４７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤

Also Published As

Publication number Publication date
US20030199493A1 (en) 2003-10-23
AU785385B2 (en) 2007-03-29
SK17022001A3 (sk) 2003-02-04
DE50101827D1 (de) 2004-05-06
CN1380883A (zh) 2002-11-20
NO20015857D0 (no) 2001-11-30
NZ516302A (en) 2004-02-27
PL352638A1 (en) 2003-09-08
SI1181294T1 (en) 2004-08-31
ATE263171T1 (de) 2004-04-15
PL202463B1 (pl) 2009-06-30
SK285909B6 (sk) 2007-10-04
IS2287B (is) 2007-10-15
WO2001074820A1 (de) 2001-10-11
MXPA01012275A (es) 2003-06-24
CZ300160B6 (cs) 2009-02-25
BG65134B1 (bg) 2007-03-30
ES2215885T3 (es) 2004-10-16
EP1181294A1 (de) 2002-02-27
NO326458B1 (no) 2008-12-08
BG106155A (en) 2002-08-30
HK1045990A1 (en) 2002-12-20
TR200400857T4 (tr) 2004-06-21
CZ20014178A3 (cs) 2002-11-13
HUP0202233A3 (en) 2004-12-28
PT1181294E (pt) 2004-07-30
AU4208501A (en) 2001-10-15
NO20015857L (no) 2002-01-29
US7166588B2 (en) 2007-01-23
HK1049832A1 (zh) 2003-05-30
EP1181294B1 (de) 2004-03-31
US20070027138A1 (en) 2007-02-01
DK1181294T3 (da) 2004-08-02
CA2368966A1 (en) 2001-10-11
IS6174A (is) 2001-11-23
RU2241001C2 (ru) 2004-11-27
BR0105563A (pt) 2002-04-02
HUP0202233A2 (hu) 2002-11-28

Similar Documents

Publication Publication Date Title
JP2003529602A (ja) ガランタミンの新規誘導体および類似体
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN114641473A (zh) Brd9双官能团降解剂及其使用方法
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
CN101305011B (zh) 吡啶衍生物及其在治疗精神障碍中的用途
CN103097364B (zh) 作为s1p调节剂的螺-哌啶衍生物
TW202043217A (zh) Ｂｃｌ－２抑制劑
WO2023174175A1 (zh) Kif18a抑制剂
CN112105610A (zh) 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
JP2023539194A (ja) Ａｐｏｌ１の阻害剤およびこれを使用する方法
WO2024088408A1 (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
TW201605859A (zh) 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
JP3406600B2 (ja) キノリン誘導体又はその塩，及びこれを含有する心疾患治療剤
CN102083832B (zh) 作为NK1 Tachikynin受体的拮抗剂的螺(哌啶-4，2′-吡咯烷)-1-(3，5-三氟甲基苯基)甲基甲酰胺
KR100768245B1 (ko) 신규한 갈란타민 유도체 및 유사체
EP3768679A1 (en) Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
WO2024251040A1 (zh) Irak4降解剂及其用途
EA052303B1 (ru) Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения
WO2024208187A1 (zh) 氮杂芳基化合物及其作为lsd1抑制剂的用途
WO2025218811A1 (zh) pan-KRAS靶向蛋白降解剂及其制备方法和应用
HK40121692A (zh) 一种tdg抑制剂化合物及其用途
WO2024067676A1 (zh) 作为sumo活化酶抑制剂的化合物
TW202444345A (zh) 大環雜環化合物及其用途
JPH0832706B2 (ja) 生理活性物質ｋ‐２５２の誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706